Regen BioPharma, Inc. to Present at the Emerging Growth Conference on February 8, 2023

Regen BioPharma, Inc. invites individual and institutional investors as well as advisors and analysts to attend its real-time, interactive presentation at the Emerging Growth Conference.

SAN DIEGO, Feb. 7, 2023 /PRNewswire/ -- Regen BioPharma, Inc. RGBP and RGBPP, a biotechnology company advancing a diverse pre-clinical pipeline spanning cell therapies, RNA vaccines, RNA and DNA therapeutics and small molecule drugs will be presenting at the Emerging Growth Conference on February 8, 2023 (https://emerginggrowth.com/conference/).

This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's CEO, Dr. David Koos, in real time. Please ask your questions during the event and Dr. Koos and his team will do their best to address as many of them as possible.

"We plan to use this time to update our stakeholders on our corporate strategic plans, drug pipeline, drug development strategy and answer shareholder questions," says Dr. David Koos, CEO and Chairman of the Company. "We also plan to address Regen's forthcoming 1for1500 reverse stock split affecting all series of stock. We feel that effecting this change is integral to furthering the Company's objectives of seeking uplistings for our Common and series A Preferred Stock as well as making our stock more attractive to institutional investors."  The reverse stock split will be effective March 6, 2023.   

Regen BioPharma, Inc. will be presenting from 2:20 - 2:50 Eastern time on Wednesday, February 8, 2023. Please register here to ensure you are able to attend the conference and receive any updates that are released https://goto.webcasts.com/starthere.jsp?ei=1589451&tp_key=60f8292c14&sti=rgbp. 

If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available on EmergingGrowth.com.

About the Emerging Growth Conference

The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.

The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of individual and institutional investors, as well as investment advisors and analysts.

About Regen BioPharma Inc.: 

Regen BioPharma, Inc. is a publicly traded biotechnology company RGBP and RGBPP. The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on mRNA and small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.

Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

CONTACT INFORMATION

Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
david.koos@regenbiopharmainc.com
+1-619-722-5505 Phone
+1-619-330-2328 Fax

Follow us on Twitter for future updates: https://twitter.com/TheRegenBio

SOURCE Regen BioPharma Inc.